Ed Saltzman
Executive Chairman
esaltzman@definedhealth.com
Ed Saltzman is President and Founder of Defined Health, a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors. Leveraging 25+ years of experience consulting for biopharma companies, he provides guidance to Defined Health’s senior project leadership who work with clients across multiple therapeutic areas. Ed is an in demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. He notably coined the term “Proof of Relevance,” to describe indisputable demonstration of clinical and economic value in drug development. He is a recent recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Ed is an advisor to the Israel Biotech Fund, and a member of the Licensing Executives Society (LES) and the New York Pharma Forum. He is a graduate of New York University.
- Pricing and Paying for Progress: Disrupting the BioPharma Business Model
- Pricing and Paying for Progress: Disrupting the BioPharma Business Model, LES Annual Meeting, October 25, 2016, Vancouver
- The Future is Now: Dealing in a Transformed Healthcare Environment
- Connecting drug pricing to value: The industry’s greatest challenge
- The Future is Now: Dealing in a Transformed Healthcare Environment
- Changes to Biopharma’s External Ecosystem That Will Bring Permanent Changes to the Biopharmaceutical Industry
- Foundational Changes in the Biopharmaceutical and Healthcare Macro Environments . . . and the Impacts on Licensing & Business Development
- Establishing Proof of Relevance for Early Stage Deal Making
- Pharma Steps Up Early on Relevance Data
- Connecting Proof of Relevance to Proven Value for Pharma